Different effects of the three polymorphisms on 15q25.1 onlung cancer risk: Evidence from published literatures.

Huiling Sun,Yuqin Pan,Bangshun He,Qiwen Deng,Houqun Ying,Jie Chen,Xian Liu,Shukui Wang
DOI: https://doi.org/10.4103/0973-1482.151863
2016-01-01
Journal of Cancer Research and Therapeutics
Abstract:Aim of Study: Genetic studies have shown a significant association between lung cancer risk and single nucleotide polymorphisms on chromosome 15q25.1. The potential association of three polymorphisms in the CHRNA3 (rs1051730(G > A)), CHRNA5 (rs16969968(G > A)), and AGPHD1 (rs8034191(A > G)) with the lung cancer risk has been widely investigated, but the results are inconsistent. The aim of meta-analysis was toclarify the link between three polymorphisms and susceptibility to lung cancer. Materials and Methods: All the relevant data were retrieved by Embase, PubMed, and Web of Science, and then 38 eligible studies were chosen in this meta-analysis. Results: There was no association of rs16969968 polymorphism with cancer risk in the overall pooled analysis. For the rs1051730 and rs8034191 polymorphisms, the results revealed that the five models were significantlyassociated with elevated risk of cancer. Further stratified analysis indicated that increased risk for lung cancer was foundinthe Caucasian, African American, and Asian population. Conclusion: In summary, CHRNA3rs1051730 (G > A) and AGPHD1rs8034191 (A > G) were more susceptible to lung cancers than noncarriers.
What problem does this paper attempt to address?